Replimune stock advances as TUDRIQEV launch gains traction

Published on 10/31/2026 at 01:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Replimune stock follows an early commercial launch for TUDRIQEV in advanced melanoma. The company also reported a narrower quarterly loss.

Launch Progress and Financial Update

Replimune reported a narrower fiscal second-quarter loss and continued its commercial rollout of TUDRIQEV.
The melanoma therapy has reached early users, while the IGNYTE-3 confirmatory study remains on track.
Cash reserves are intended to fund operations for more than twelve months, keeping commercialization execution in focus.

REPL, US76029N1063, Illustration mit AI erstellt.

Replimune reported fiscal second-quarter results on October 28, 2026, alongside an update on the commercial launch of TUDRIQEV. The company said more than 15 institutions had prescribed the therapy after its first delivery to patients on October 6. The National Law Review published the company release, which also said more than 70 percent of 200 priority accounts had been engaged.

Replimune stock traded at 15.72 euros on Lang & Schwarz at 23:00 Berlin time on Friday, October 30, 2026; the real-time quote of Replimune Group stock is available here.

Commercial Launch Meets Lower Loss

Replimune reported a net loss of 57.1 million US dollars for the quarter ended September 30, compared with 83.1 million US dollars a year earlier. Research and development expenses fell to 34.4 million US dollars from 57.9 million US dollars, while selling, general and administrative expenses declined to 21.9 million US dollars from 26.4 million US dollars.

Cash and cash equivalents stood at 307.8 million US dollars at September 30. Management said the balance should fund operations for more than twelve months, including the TUDRIQEV rollout and working capital. The key near-term test is whether early prescribing converts into sustained demand and revenue.

Pipeline Milestones Remain Important

TUDRIQEV is marketed in combination with nivolumab for adults with unresectable advanced cutaneous melanoma after progression on a PD-1-blocking antibody-based regimen. Its accelerated approval depends on confirmation of clinical benefit in ongoing studies. Replimune said the global Phase 3 IGNYTE-3 trial remains on track, while the registration-directed RP2 REVEAL study is actively enrolling.

Specialist Biotech in Oncology

Replimune is a United States biotechnology company focused on oncolytic immunotherapies that use engineered herpes simplex virus technology to stimulate anti-tumor immune responses. Its commercial focus is TUDRIQEV in advanced melanoma, while RP2 and other RPx candidates expand the pipeline across solid tumors. The company is headquartered in Woburn, Massachusetts.

Replimune operates as a smaller, specialized oncology developer than diversified pharmaceutical companies such as Amgen and Bristol Myers Squibb. Those larger groups bring broader commercial portfolios and established oncology franchises, while Replimune is concentrating on its oncolytic immunotherapy platform and the early adoption of TUDRIQEV.